

Media Release

Zug, 27 April 2017

HBM Healthcare Investments commits EUR 20 million in growth capital to Switzerland based Amicus SA

HBM Healthcare Investments today announced the closing of a new equity investment of EUR 20 million in two tranches into the privately held and Switzerland based Amicus SA. The financing will allow Amicus to accelerate the growth of its pharmaceutical business in Central and Eastern Europe (CEE).

Amicus is a revenue generating company and was established by the former founders of PharmaSwiss SA, in which HBM Healthcare Investments was a significant shareholder from 2007 until 2011 when the company was sold. The company specializes in the distribution of pharmaceutical products, medical equipment and over the counter brands in countries where the originators decide not to maintain a direct presence. Leading healthcare companies such as Alcon, Bristol Myers Squibb, Cardinal Health, Expanscience, Grupo Ferrer, General Electric, Genexo, Pfizer, PharmaNutra and Salvat Biotech, amongst others, are represented by Amicus.

For further information, please contact Dr. Andreas Wicki on +41 41 710 75 77, or at andreas.wicki@hbmhealthcare.com

Information on HBM Healthcare Investments Ltd

HBM Healthcare Investments invests in the healthcare sector. The Company holds and manages an international portfolio of promising companies in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided in their strategic direction. This is what makes HBM Healthcare Investments an interesting alternative to investments in big pharma and biotechnology companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA

HBM Healthcare
Investments

Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (*Wertpapierprospektgesetz*). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM Healthcare Investments Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.

HBM Healthcare Investments Ltd

Bundesplatz 1 CH-6300 Zug | Tel: +41 41 710 75 77 | Fax: +41 41 710 75 78 | info@hbmhealthcare.com
www.hbmhealthcare.com